Document is current

Article History

Accepted: 1 October 2024

First Online: 7 January 2025

Declarations

:

: All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

: Drs. Puri and Altisent serve as a consultants to Products & Features. Dr. Puri is a consultant to VDyne, and PI of TRICAV-1 and TRICAV-2 trials. Dr. Chen has nothing to disclose.

: Blasco-Turrión S, Briedis K, Estévez-Loureiro R, Sánchez-Recalde A, Cruz-González I, Pascual I, et al. Bicaval TricValve Implantation in Patients With Severe Symptomatic Tricuspid Regurgitation. JACC Cardiovasc Interv. 2024;17:60–72.<b>This Analysis Describes the 1-year Clinical Endpoints from the TricValve single-arm Interventional CAVI Experience</b>.Denby K, Spilias N, Harb SC, Kapadia SR, Puri R. Contrast-Sparing Intravascular Ultrasound–Guided Caval Valve Implantation for Severe Symptomatic Tricuspid Regurgitation. JACC Case Rep. 2023;23:102007.<b>This series describes contrast-sparing techniques for CAVI that utilize IVUS, important due to the prevalence of chronic kidney disease in patients with severe tricuspid regurgitation and right heart failure.</b>